NY-MEDIDATA
Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced the launch of Medidata Clinical Data Studio, a unified experience that unlocks the true power of clinical research data. This groundbreaking technology gives stakeholders greater control over the quality of data and the ability to deliver safer trials to patients faster.
Built on the Medidata Platform, Clinical Data Studio integrates data from both Medidata and non-Medidata sources, accelerating decision-making across the full clinical trial process and delivering holistic data and risk strategies that connect patients, sites, and sponsors. Through AI, study teams can more effectively identify potential data issues and safety signals, resulting in a more accurate understanding of the patient. This reduces the challenges posed by siloed data systems and enables action data review and reconciliation up to 80 percent faster.
“Clinical Data Studio unlocks the broad ecosystem of clinical data. Powered by embedded AI, we are democratizing access to data and revealing the signals, risks, and insights that matter most. Together this accelerates trial execution and creates rich data for new discoveries,” said Tom Doyle, chief technology officer, Medidata.
Clinical Data Studio offers a comprehensive workspace for data integration, transformation, and management. It includes AI-assisted data reconciliation and anomaly detection, self-serve data listings, robust risk-based quality management, and tools to implement a holistic data and risk strategy supported by workflows and visualizations.
“As data volume and sources grow exponentially, managing this data and garnering real-time insights is becoming increasingly complex. Not only is this impacting time-to-market, but it is also delaying the timely delivery of therapies to patients, thus impacting patients' lives," said Dr. Nimita Limaye, research vice president, Life Sciences R&D Strategy and Technology, IDC. “By enabling users to manage all their data, both Medidata and non-Medidata data, in one place, Medidata Clinical Data Studio has the potential to disrupt the industry by accelerating clinical trials and getting therapies to patients faster.”
About Medidata
Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 33,000 trials and 10 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across 2,200+ customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.
About Dassault Systèmes
Dassault Systèmes is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all –consumers, patients and citizens. Dassault Systèmes brings value to more than 350,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit www.3ds.com
© Dassault Systèmes. All rights reserved. 3DEXPERIENCE, the 3DS logo, the Compass icon, IFWE, 3DEXCITE, 3DVIA, BIOVIA, CATIA, CENTRIC PLM, DELMIA, ENOVIA, GEOVIA, MEDIDATA, NETVIBES, OUTSCALE, SIMULIA and SOLIDWORKS are commercial trademarks or registered trademarks of Dassault Systèmes, a European company (Societas Europaea) incorporated under French law, and registered with the Versailles trade and companies registry under number 322 306 440, or its subsidiaries in the United States and/or other countries. All other trademarks are owned by their respective owners. Use of any Dassault Systèmes or its subsidiaries trademarks is subject to their express written approval.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240618137167/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bureau Veritas:A Robust First Quarter and an Unchanged 2025 Outlook; Increased Returns to Shareholders with a EUR 200m Share Buyback Program24.4.2025 07:30:00 CEST | Press release
Bureau Veritas (BOURSE:BVI): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423971668/en/ Hinda Gharbi, CEO at Bureau Veritas Q1 2025 Key figures1 › Revenue of EUR 1,558.7 million, up 8.3% year-on-year and up 7.3% organically › Strong organic growth from Industry at +14.3%, Marine & Offshore at +11.8% and Certification at +10.9% with moderate growth for Agri-Food & Commodities at +6.0%, Consumer Products Services at +3.4%, and Buildings & Infrastructure at +2.5% › Positive scope effect of 1.4%, from bolt-on acquisitions (+3.0% contribution), net of disposals (-1.6% contribution) › Negative currency impact of 0.4%, resulting from the euro’s appreciation against most currencies Q1 2025 Highlights › Steady and consistent growth in every region, demonstrating clear business plans and showing strong execution › Broad growth across all activities. Capex activities driven by a solid backlog, and Opex activities derived from sust
Galderma Delivers Record First Quarter Net Sales of 1.129 Billion USD, Including Strong Performance From Two Launches With Blockbuster Potential, and Confirms Full-Year Guidance24.4.2025 07:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2025. Net sales: Achieved 1,129 million USD in net sales, up 8.3% year-on-year on a constant currency basis, primarily driven by volume, complemented by favorable mix Results ahead of expectations: Net sales benefited from focused execution, favorable phasing in Injectable Aesthetics, and stronger than expected ramp-up of Nemluvio Broad-based growth: Strong performance momentum across product categories and across geographies, with constant currency year-on-year growth of 9.9% for Injectable Aesthetics, 7.8% for Dermatological Skincare, and 4.9% for Therapeutic Dermatology, which includes net sales of 39 million USD for Nemluvio® (nemolizumab) Innovation, science and education leadership: Further advanced its category leadership in dermatology: with the launch of Nemluvio and Relfydess™ (RelabotulinumtoxinA),
Engelhart and e.optimum Strengthen Their Partnership With a Further Onshore Wind PPA, Supporting Germany’s Energy Transition24.4.2025 07:00:00 CEST | Press release
The Global Commodities and Renewable Energy Trader, Engelhart, is delighted to announce the signing of a further power purchase agreement (PPA) with e.optimum, one of Germany’s largest independent energy suppliers. Following the first PPA signed in January 2025, this new agreement secures renewable electricity from additional onshore wind turbines with a total capacity of approximately 167 MWfromJuly to December 2025. This is enough green power to supply around 31,000 households. This second PPA marks a significant expansion of the partnership between the two companies. It represents a 195% increase in contracted capacity, bringing the total from 86 MW to 253 MW of onshore wind power. Furthermore, the agreement contributes directly to Germany’s transition to a net zero-carbon economy by 2045. Matthias Seel, Senior Originator Corporate Customers Europe at Engelhart, commented: "The second PPA with e.optimum is another milestone in our joint partnership. Especially in uncertain economic
Textron Aviation Raises the Bar for Workforce Development With State-of-the-Art Career & Learning Center23.4.2025 22:00:00 CEST | Press release
Textron Aviation Inc. a Textron Inc. (NYSE: TXT) company, today announced its new Career & Learning Center is complete and fully operational serving prospective, current and future Textron Aviation employees. Strategically located on the company’s East Wichita Campus, this state-of-the-art facility expands the training footprint to more than 75,000 square feet and provides a world-class employee experience during the application, hiring, onboarding and training processes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423874476/en/ Textron Aviation Career and Learning Center | Textron Aviation “The Textron Aviation Career & Learning Center is an important investment in building the next generation of aviation manufacturing, support and professional talent,” said Ron Draper, president and CEO. “Recruiting, hiring and training a world-class workforce is vital to our ability to provide the best aviation experience for our cu
TSMC Unveils Next-Generation A14 Process at North America Technology Symposium23.4.2025 20:40:00 CEST | Press release
Showcasing TSMC’s latest offerings for high performance computing, smartphone, automotive, and IoT applications TSMC (TWSE: 2330, NYSE: TSM) today unveiled its next cutting-edge logic process technology, A14, at the Company’s North America Technology Symposium. Representing a significant advancement from TSMC’s industry-leading N2 process, A14 is designed to drive AI transformation forward by delivering faster computing and greater power efficiency. It is also expected to enhance smartphones by improving their on-board AI capabilities, making them even smarter. Planned to enter production in 2028, the current A14 development is progressing smoothly with yield performance ahead of schedule. Compared with the N2 process, which is about to enter volume production later this year, A14 will offer up to 15% speed improvement at the same power, or up to 30% power reduction at the same speed, along with more than 20% increase in logic density. Leveraging the Company’s experience in design-tech
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom